Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
the primary objective is to characterise the impact of gefitinib on the Response Evaluation
Criteria in Solid Tumours (RECIST) based assessments; objective response rate (ORR ;
confirmed complete response(CR) or partial response (PR)) and disease control rate (DCR;
confirmed complete response(CR) or partial response (PR) or stable disease (SD)) in patients
with EGFR M+ NSCLC